Abstract: Differentiated thyroid cancer(DTC) has become the most common head and neck tumor, and most DTC patients have a good prognosis after treatment. However, patients with metastasis and loss of differentiation have a poor prognosis and lack of effective diagnosis and treatment. Radiopharmaceuticals targeting prostate specific membrane antigen (PSMA) have been used in imaging and treatment of patients with prostate cancer, but the research on DTC is still at the exploratory stage. In this paper, the application status and prospect of targeted PSMA imaging and treatment of DTC were reviewed, and the future perspectives were also presented.